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Background: Polycystic ovary syndrome (PCOS) is a common condition in women of reproductive age. It is
characterized by hyperandrogenism, oligomenorrhea/amenorrhea and polycystic ovaries. It is associated with
obesity, diabetes, dyslipidemia and cardiovascular disease. No studies have been conducted on the prevalence of
PCOS in Brazilian or South American women. Few studies using the Rotterdam criteria have been published. The
objective of the present study was to calculate the prevalence of PCOS at primary healthcare level in Salvador,
Brazil based on these criteria.
Methods: This was a cross-sectional, two-phase study conducted in a probability sample of women of 18–45 years
of age screened for cervical cancer in the primary healthcare network of the city of Salvador, Brazil. In the first
phase, interviews were conducted, weight, height, waist circumference, blood pressure and random blood sugar
levels were measured, and the presence of acne and hirsutism was investigated. Women with at least one
diagnostic criterion were referred for the second phase, which consisted of specialist consultation, pelvic
ultrasonography and hormone measurements for differential diagnosis and/or investigation of a second criterion.
Results: Of the 859 women interviewed, 88.5% were black and 58.7% had 11 years of schooling or less. A diagnosis
of PCOS was excluded in 84.4%, undetermined in 7.1% and confirmed in 8.5% (95%CI: 6.80–10.56). There were no
statistically significant differences between these three groups with respect to weight, body mass index, waist
circumference, blood sugar levels or arterial blood pressure. Women with PCOS were younger (p = 0.00), taller
(p = 0.04), had fewer children (p = 0.00), were better educated (p = 0.01), and had higher total testosterone levels
(p = 0.01) and a higher LH/FSH ratio (p = 0.01).
Conclusion: According to the Rotterdam criteria, the prevalence of PCOS in women seeking primary healthcare in
Salvador, Brazil, was 8.5%.
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Women’s healthBackground
Polycystic ovary syndrome (PCOS) is characterized by
anovulation, hyperandrogenic symptoms and infertility
[1-3]. PCOS is a hyperinsulinemic syndrome strongly
associated with obesity and type 2 diabetes mellitus and
has also been associated with high blood pressure, dysli-
pidemia and cardiovascular disease [2]. It is the most* Correspondence: ligiagabrielli@uol.com.br
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distribution, and reproduction in any mediumcommon endocrinopathy in women of reproductive age
and is identifiable in early adolescence [4-6].
PCOS must be diagnosed as early as possible in order
to prevent and treat associated conditions and ultimately
reduce cardiovascular morbidity and mortality [7,8].
Nevertheless, the disorder is commonly underdiagnosed,
making it impossible to promote preventive measures
such as dietary control, physical activity and, whenever
required, pharmacological treatment for insulin resist-
ance and associated diseases [9,10]. The heterogeneity in
the clinical signs of PCOS and the lack of uniformity
in its defining symptoms hamper diagnosis. In recent
years, specialists have attempted to reach a consensusCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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the National Institutes of Health (NIH) established that
a diagnosis of PCOS required the simultaneous presence
of two clinical criteria: oligoovulation or anovulation and
clinical and/or biochemical hyperandrogenism, after all
other possible etiologies had been excluded. In 2003, the
Rotterdam Consensus (RC), sponsored by the European
Society for Human Reproduction and Embryology
and the American Society for Reproductive Medicine,
stipulated that at least two of the following three
criteria should be present: oligoovulation or anovula-
tion, clinical and/or biochemical hyperandrogenism
and ultrasonographically detected polycystic ovaries,
after the exclusion of all other possible etiologies [11].
The criterion concerning ovarian morphology was
added to the initial diagnostic criteria; however, it is
absent in 5–20% of cases [10,12]. The inclusion of phe-
notypes unrelated to hyperinsulinism remains under
debate. Some authors argue that PCOS is a prima-
rily hyperandrogenic condition; therefore, phenotypes
that do not include this feature should not be accepted
as such [13]. The presence of some of the relevant clin-
ical aspects or all of them appears to be related to a
greater or lesser degree to insulin resistance and to
the metabolic syndrome [13,14], which may determine
prognosis.
Until a few years ago, the prevalence studies con-
ducted on PCOS were restricted to the United States
and some European countries, with reported rates
that ranged from 4.6 to 8.0% [6,14-18]. This varia-
tion may be explained by differences in methodology
and in the age-group and ethnicity of the sample
populations [19].
Investigators from developing countries with diverse
ethnic populations were encouraged to conduct their
own evaluations. In July 2008, two studies on the preva-
lence of PCOS were published simultaneously: a Sri Lankan
population-based survey that used the RC criteria to
evaluate 2,915 women and reported a prevalence of 6.3%
[10], and a Chinese study that evaluated 915 women
attending a healthcare unit and reported a prevalence of
2.2% using the NIH criteria [12]. In a Mexican study
published in 2010, a prevalence of PCOS of 6.0% was
reported in a voluntary population of 150 women in
Mexico City [20]. This finding differs from an earlier
estimate of 12.8% in Mexican-American women [21]. A
recent publication showed an estimated prevalence of
14.6% in Iranian women evaluated in accordance with the
Rotterdam criteria [22].
The objective of the present study was to estimate the
prevalence of PCOS in Salvador, Brazil. It was expected
that the ensuing results would enable clinical protocols
to be created to detect the disorder at an early stage at
primary healthcare level.Methods
Design, study population and sample
This cross-sectional study was carried out in the city of
Salvador, Brazil with women of 18–45 years of age
attending primary healthcare units for cervical cancer
screening in all the sanitary districts of the city. This
population was selected because screening is aimed at
“healthy” women, neither selecting nor excluding any
woman in the age-group of interest. Stratified sampling
[23] was adopted according to the sanitary district, mak-
ing a total of 12 strata, with one randomly selected unit
in each district. The work shifts during which the sub-
jects would be approached were also chosen at random
by elaborating a schedule of preestablished dates on
which to conduct the study at each center.
The calculated sample size (n = 850) was distributed
proportionally in accordance with the total number of
consultations conducted previously in each district. The
STATA software program, version 9.0 (Stata Corp.,
College Station, Texas, USA) was used to calculate sam-
ple size and randomize sample units.
The age-group was selected to include the reproduct-
ive years. The lower limit was established at 18 years,
since this is the age of legal majority, thereby making it
simpler to obtain participants’ informed consent. The
upper limit was set at 45 years of age despite the fre-
quent occurrence of menopause-related menstrual disor-
ders in women over 40 years of age that could be
confused with PCOS symptoms. Nevertheless, FSH
levels were measured in all women with menstrual dys-
function to identify any menopausal women. All partici-
pants with FSH levels > 25 mIU/ml were excluded from
the study, as were those taking any exogenous sex ster-
oid hormones as contraception or hormone therapy.
Phase 1: Screening at primary healthcare level
This project was previously approved by the relevant
municipal health authorities and by the internal review
board of the Bahia State Referral Center for Diabetes
and Endocrinology (CEDEBA) (SISNEP # 156299). Writ-
ten informed consent was obtained from all the partici-
pants of this study.
Pregnant or nursing women and those with cognitive
and/or physical limitations that prevented them from
answering the questionnaire were excluded from the
study.
The questionnaire was pretested at a gynecological
endocrinology outpatient clinic (CEDEBA) and a pilot
study was conducted with users of a primary healthcare
unit that did not participate in the study.
A structured questionnaire was applied face-to-face to
obtain information on the identification of the patients
as well as their sociodemographic data, information on
their pubertal, menstrual, sexual and reproductive
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PCOS, any related treatment and the presence of any
hyperandrogenic symptoms. Immediately after this inter-
view, an independent examination was made to verify
the presence of hirsutism, significant acne or alopecia.
Hirsutism was rated according to the modified
Ferriman-Gallwey (FG) scoring system. To standardize
findings all participants were evaluated by the same
investigator.
To screen for PCOS in the primary healthcare units,
women with a history of amenorrhea/oligomenorrhea
(defined as an intermenstrual interval ≥35 days) or ab-
normal uterine bleeding (AUB) associated with anovula-
tion (defined as genital bleeding of 10 days or more at
irregular intervals of less than 25 days and no other pos-
sible cause, as confirmed at the consultation in phase 2
of the study) were identified from their answers to the
questionnaire. Women were considered hirsute when
they scored ≥ 6 points on the FG scale [24,25]. Clinical
hyperandrogenism was also identified from the presence
of moderate to severe acne scoring 3 or 4 in the Investi-
gator’s Global Assessment (IGA) and defined by the
presence of frequent noninflammatory comedones and a
varying number of papulopustular or nodular lesions
with inflammatory characteristics [26].
Weight, height, arterial blood pressure, waist cir-
cumference and random blood sugar levels were mea-
sured in all participants at the primary healthcare units
using standardized methodology. Quality control was
carried out by systematically retesting around 10% of
participants.
Phase 2: Specialist consultation at secondary
healthcare level
Women with one or more clinical criteria or a prior
diagnosis of PCOS, even in the absence of any signs or
symptoms, were referred for the second phase of the
study to be carried out at the gynecological endocrin-
ology outpatient department, where one or more spe-
cialist consultations were provided. Fasting blood
samples were taken from all the participants to measure
FSH, LH, TSH, PRL and total testosterone (T) levels
using standardized chemiluminescent immunometric
assays with the Immulite 1000 immunoassay system
(Diagnostic Products Corporation, Los Angeles, USA)
and 17α-hydroxyprogesterone by radioimmunoassay
(Bio Source Europe S.A., Nivelles, Belgium). Total T
levels were considered high when they were above the
95th percentile of the women evaluated and classified as
normal at the end of the investigation. For budgetary
reasons, ovarian morphology was evaluated by ultrason-
ography only in women who were found to have at least
one criterion in the first phase of the study and who
went on to participate in the second phase, and for thesole purpose of seeking a second diagnostic criterion or
excluding other causes of AUB. The same specialist per-
formed ultrasonography in all cases. Ovaries were
defined as polycystic when ≥12 follicles measuring 2–
9 mm in diameter and/or follicles with a volume
>10 cm3 were found (12). An Aloka Pro-Sound ultra-
sound scanner, model SSD-5500 PHD (Aloka Corpor-
ation Ltd., Tokyo, Japan) was used for the study.
A diagnosis of PCOS was given to all the women who
fulfilled the diagnostic criteria defined in the RC, i.e.
when two of the three clinical criteria were present
(oligomenorrhea/amenorrhea, clinical or biochemical hy
perandrogenism and ultrasonographically detected poly-
cystic ovaries) and after all other possible etiologies such
as hyperprolactinemia, thyroid dysfunction, nonclassic
adrenal hyperplasia (NCAH) and Cushing’s syndrome
had been excluded [11].
Statistical analysis
The prevalence of PCOS in the study population was
calculated with a 95% confidence interval (95%CI)
according to the method recommended by Agresti and
Coull [27]. In the bivariate analysis, the different socio-
demographic, clinical and biochemical characteristics of
the women with PCOS were compared with those of the
women in whom PCOS was undetermined and those
without PCOS. To verify the null hypothesis of equality
between the groups of women with and without PCOS,
Student’s t-test was used to compare means, the Mann–
Whitney test for medians and Pearson’s chi-square test
for proportions. Gradients were evaluated using Cuzick’s
test for trend [28]. Statistical analysis was performed
using the Stata software program, version 9.0 (Statcorp,
College Station, USA).
Results
Of all the eligible women screened for the study, 859
were interviewed, yielding a response rate of 96.1%. The
mean age of the subjects was 30.7 ± 7.2 years, 88.5%
were black (according to the ethnic classifications of the
Brazilian Institute of Geography and Statistics) and
62.8% were in a stable marital relationship. The propor-
tion of women in paid employment at the time of the
interview was 54.5% (n = 468). Of these, 75.2% (n = 352)
earned one minimum wage or less and 95.3% (n = 446)
earned a maximum of two minimum wages.
Of all women in the study, 181 (21.1%) were classified
as having one (13.6%) or two (5.8%) diagnostic criteria
or, alternately, having previously been diagnosed with
PCOS despite having no clinical criteria whatsoever
(1.6%). These women were then referred to the second
phase of the trial (Figure 1) and 107 (59.1%) attended
the specialist consultation. Of these, 91.6% underwent
hormone evaluation and 57.9% were referred for
Figure 1 Flowchart of the study population. Flowchart of the study population from the moment of screening in the primary healthcare units
to further diagnostic assessment at the specialist consultation and referral for supplementary tests, concluding with the final classification. Study
on the prevalence of polycystic ovary syndrome at primary healthcare level in Salvador, Brazil, 2008 (n = 859). * Non-classic adrenal hyperplasia.
** Polycystic ovary syndrome.
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those who failed to attend the specialist visit, 24.7%
already had two criteria, thus constituting a diagnosis
of PCOS.
A total of 73 women fulfilled the prerequisites for a
diagnosis of PCOS according to the RC criteria, resulting
in an estimated prevalence of 8.5% (95%CI: 6.80 - 10.56).
When the NIH diagnostic criteria were applied, 69 cases
of PCOS were found, with a prevalence of 8.03% (95%CI: 6.39 - 10.05). Of the 859 women participating in the
study, 84.4% were considered not to have PCOS. In
those women with only one criterion who failed to at-
tend the specialist consultation in the second phase of
the study or who attended the consultation but failed to
complete the evaluation, PCOS was considered undeter-
mined (7.1%) (Figure 1).
When comparing measurements between the three
groups of women in whom PCOS was confirmed,
Table 1 Sociodemographic, anthropometric, clinical and biochemical characteristics of women participating in a study
on the prevalence of PCOS, Salvador, Brazil, 2008 (n = 859)
Variables PCOS Confirmed PCOS Undetermined Non-PCOS Statistical Test b
(n =73) a (n =61) (n =725)
Mean (SD) c Mean (SD) Mean (SD) Student’s t-test
Age 28.4 (6.5) 29.3 (7.3) 31.0 (7.3) 0.00
Number of children 0.9 (1.1) 1.2 (1.4) 1.5 (1.3) 0.00
Years of schooling 9.7 (2.7) 8.2 (3.0) 8.6 (2.9) 0.00
Height (meters) 1.61 (0.07) 1.60 (0.05) 1.59 (0.06) 0.04
Median (IQR) d Median (IQR) Median (IQR) Mann–Whitney test
Measurements
Weight (kg) 60.9 (37.7 – 84.1) 60.8 (44.3 – 77.3) 61.1 (45.1 – 77.1) 0.50
Body mass index (kg/m2) 24.2 (17.7 – 30.7) 23.7 (18.1 – 29.3) 24.1 (18.1 – 30.1) 0.92
Waist circumference (cm) 74 (56 – 92) 74 (56 – 92) 75 (60 – 90) 0.60
Random blood sugar e 92 (71 – 114) 93 (71 – 115) 92 (72 – 112) 0.67
Systolic blood pressure (mmHg) 119 (99 – 139) 118 (96 – 140) 122 (102 – 142) 0.31
Diastolic blood pressure (mmHg) 74 (60 – 88) 74 (59 – 89) 74 (59.5 – 89.5) 0.92
Mean arterial pressure (mmHg) 97.5 (81 – 114) 96.5 (79 – 114) 98.5 (81 – 116) 0.48
Total testosterone f 52 (20 – 82) NA g 35 (16 – 54) 0.00
LH/FSH ratio h 1.31 (−0.15 – 2.77) 1.04 (−3.16 – 5.24) 0.82 (−0.1 – 1.76) 0.01
(%) (%) (%) χ2
PCOS Diagnostic Criteria
Oligomenorrhea i 98.6 34.4 2.5 0.00
Hirsutism j 79.5 47.5 3.1 0.00
Total testosterone ≥ 95th percentile k 44.0 25.0 14.3 0.00
Polycystic Ovaries l 15.1 m NA n — 0.01
Sociodemographic Characteristics
Race/skin color/ethnic group
Black 90.8 91.2 88.1 0.65
Education (years of schooling) 0.01
Did not complete primary school (<8) 16.4 39.3 29.4
Completed primary school (= 8) 21.9 18.0 28.9
Completed secondary school (= 11) 53.4 41.0 39.6
University (>11) 8.22 1.64 2.1
Marital status
Stable relationship 65.8 55.7 63.0 0.45
Employment status
In paid employment 43.8 55.7 55.4 0.16
Associated Clinical Conditions
Blood pressure≥ 140/90 mm Hg 17.8 18.6 19.1 0.96
Obesity (BMI o ≥ 30 kg/m2) 13.7 18.6 12.3 0.37
Random blood sugar ≥ 100 mg/dl 32.9 39.3 33.4 0.66
a Polycystic Ovary Syndrome according to the criteria defined in the Rotterdam Consensus. b Statistical tests comparing “confirmed PCOS” with “non-PCOS”.
c Standard deviation. d Interquartile range. e Random blood sugar in mg/dl. f Total serum testosterone (ng/dl). g Not available (undetermined). h LH and FSH in
mIU/ml. i Menstrual cycles ≥ 35 days or anovulatory dysfunctional uterine bleeding. j Ferriman-Gallwey (FG) score ≥ 6. k Total serum testosterone ≥ the 95th
percentile of women with no diagnostic criteria (58 ng/dl). l By pelvic ultrasonography according to the imaging criteria defined in the Rotterdam Consensus,
2003. m Performed only to search for a second criterion. n Not available. o Body mass index.
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the groups with respect to all the measurements that
attained statistical significance, indicating that there
were probably some cases of PCOS in the undetermined
group that remained undetected. In the extreme possi-
bility that all the women classified as undetermined ac-
tually had PCOS, the maximum prevalence would be
15.6% (95%CI: 13.32 - 18.18).
No statistically significant differences were found be-
tween the groups with regard to weight, body mass
index, waist circumference, random blood sugar levels
or minimum, maximum or mean arterial blood pressure
(Table 1). Women with PCOS were younger (p = 0.00),
taller (p = 0.04), had fewer children (p = 0.00) and more
years of schooling (p = 0.01). Following adjustment for
age, the differences in all of these variables remained sta-
tistically significant except for height (p = 0.09) (Table 2).
With regard to the number of years of schooling, when
this variable was categorized into four education levels,
there was a clear trend towards a better education level
in the group of women diagnosed as having PCOS (p =
0.00) (Table 3). Total testosterone levels were higher in
this group (p = 0.01), with a gradient that increased
according to the number of criteria present (p = 0.00)
(Figure 2). The LH/FSH ratio was also higher in women
with PCOS (p = 0.01) and the gradient was similar to
that of testosterone with respect to the number of cri-
teria present (p = 0.00) (Figure 3).
The main characteristics of the women screened in
the first phase of the study were oligomenorrhea/
amenorrhea (54.7%) and hirsutism (59.7%) (Table 4).
Likewise, at the end of the study, 78.1% of the 73 par-
ticipants who had been classified as having PCOS were
found to have a combination of these two clinical cri-
teria. Of these, 96.3% had oligomenorrhea and 79.5%
had hirsutism. Serum testosterone measurements added
another eight cases (11%). Taking acne into consideration
for the diagnosis of PCOS and performing ultrasonog-
raphy in women with only one criterion identified an-
other four cases each (5.5%).
Prevalence rates of 12.6% and 12.9% were found for
hirsutism (FG ≥ 6) and for oligomenorrhea/amenorrhea/
AUB, respectively. Overall, 18.5% of the women in the
study had acne, which was classified as moderate toTable 2 Characteristics adjusted for age in women participati
Brazil, 2008 (n = 859)
Variables PCOS (n =73)
Mean (SD) b
Number of children 0.49 (0.14)
Years of schooling 10.10 (0.34)
Height (meters) 1.62 (0.01)
a Polycystic Ovary Syndrome.
b Standard deviation.severe in 2.5% of these cases. In addition, 0.4% of
women had androgenic alopecia. PCOS was confirmed
in one-third of the women with more severe acne and in
two-thirds of those with alopecia.
Of the 126 women who declared in the questionnaire
that they had hirsutism and the 196 who stated that they
had acne, 108 and 157 women, respectively, had these
diagnoses confirmed by the FG score or by dermato-
logical examination (sensitivity of 55.6% and specificity
of 91.1% for hirsutism and sensitivity of 51.6% and speci-
ficity of 83.4% for acne).Discussion
The present results showed a prevalence of PCOS of
8.5% (95%CI: 6.80 - 10.56) in accordance with the Rot-
terdam criteria in users of the primary public healthcare
service in the city of Salvador. When this finding was
compared with the prevalence obtained using the NIH
criteria (8.03%; 95%CI: 6.39 - 10.05), no statistically sig-
nificant difference was found, as shown by the overlap-
ping confidence intervals.
Studies conducted in the southern USA [6,15], Greece
[17] and Spain [18] reported prevalence rates of 4.6 -
6.8% using the NIH criteria. The measurements of oc-
currence were expected to increase between 39% and
50% with the use of the RC, since these criteria may in-
crease the likelihood of diagnosis [29,30]. The South
Asian study conducted in Sri Lanka and the Mexican
study reported unexpectedly low prevalence rates of
6.3% and 6.6% (95%CI: 2.3 - 10.9) despite using the RC
criteria [10,20]. In agreement with the Iranian study, the
present study showed a higher prevalence, as expected
for the criteria that were used [21]. It is important to
emphasize that the results found in the various studies
would be different if other cut-off points on the FG scale
had been used and in this respect the data are not com-
parable. In the present study, a more sensitive cut-off
point (FG ≥ 6) was selected, which led to the identifica-
tion of a greater number of cases. This was also the
choice of most of the nine principal studies on the
prevalence of PCOS published to date, in which four
used a cut-off point of FG ≥ 6 [6,12,15,17], three used
FG ≥ 8 [18,20,22] and one used FG ≥ 7 [16]. In theng in a study on the prevalence of PCOSa, Salvador,





Table 3 Education level adjusted for age in women with PCOS a participating in a study on the prevalence of PCOS,
Salvador, Brazil, 2008 (n = 859)
PR b crude (95%CI) PR adjusted (95%CI) c
Education (years of schooling)
Did not complete primary school (<8) 0.56 (0.31 - 1.00) 0.61 (0.34 - 1.09)
Completed primary school (=8) 0.76 (0.46 - 1.26) 0.73 (0.44 - 1.22)
Completed secondary school (=11) 1.35 (0.96 - 1.86) 1.30 (0.93 - 1.82)
University (>11) 3.97 (1.54 - 10.22) 4.11 (1.58 - 10.67)
a Polycystic Ovary Syndrome.
b Prevalence ratio.
c Cuzick’s trend test p = 0.00.
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ion used [14].
This study included almost all diagnostic possibilities
with the exception of the phenotype represented by
polycystic ovaries and hyperandrogenemia for which the
methodology used for screening was not applicable. To
optimize available resources, testosterone measurements
and ultrasound scans were not performed in all the
women included in the study. It was decided to ignore
these possible cases since they are less severe [31] and
less common. Their occurrence has been estimated at
0.6% in population-based samples [10] and 5.8% in
selected samples [32]. In the present study, the free an-
drogen index was not calculated and for operational rea-
sons progesterone was not measured to confirm
anovulation. It was decided that all women reporting oli-
gomenorrhea or amenorrhea would be considered an-
ovulatory [3].
Methodological challenges in achieving comparable data
This study highlights the difficulties involved in obtain-
ing information on hirsutism and acne through the use
of a questionnaire, revealing the poor sensitivity of this
method compared to medical consultation or examin-















0 1 2 3
Number of clinical criteria p=0.000 
Figure 2 Testosterone levels according to the number of
clinical criteria.questionnaire, 44% fewer cases of hirsutism and 48%
fewer cases of acne were identified compared to those
found when the FG score or skin examination were
used, both of which were performed in the entire study
population. Since body image is constructed as a func-
tion of social concepts, what is considered to constitute
“excess” body hair is profoundly influenced by cultural
elements in a given population. Therefore, response to a
questionnaire on these aspects is obligatorily loaded with
individualized symbolic meanings that are difficult to
standardize. Ethnic diversity in itself brings cultural di-
versity that is often reflected in the way one sees one’s
own body, including skin characteristics and hair distri-
bution. In the case of hirsutism, it would therefore be
recommendable to carry out further analysis using an
anthropological approach on the series of symbolic
meanings associated with the answers to the study ques-
tionnaires in order to attempt to incorporate cultural
aspects when formulating questions.
Ethnic differences must be taken into consideration
when analyzing studies on PCOS. In a Chinese article,
no cases of hirsutism were found among 915 women
[12]. Other investigators have already reported a low
prevalence of hirsutism in Asian women [33,34]. On the
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Figure 3 LH/FSH ratio according to the number of clinical
criteria.
Table 4 Characteristics of women in the different phases of the study on the prevalence of PCOS, Salvador, Brazil,
2008 (n = 859)
Phase 1 – Characteristics (n1 =181) n % Phase 2 - Phenotypes (n2 =73) n %
Oligomenorrhea/amenorrhea 99 54.7 Oligo/amenorrhea and hirsutism b 57 78.1
Hirsutism b 108 59.7 Oligo/amenorrhea and high testosterone levels d 8 10.9
Moderate to severe acne c 21 11.6 Oligo/amenorrhea and acne c 4 5.5
Abnormal uterine bleeding 5 2.8 Oligo/amenorrhea and polycystic ovaries a 3 4.1
Androgenic alopecia 3 1.7 Hirsutism and polycystic ovaries 1 1.4
aRotterdam Consensus Criteria bFerriman-Gallwey score ≥ 6 cModerate to severe forms (Investigator’s Static Global Assessment) d ≥ 95 th percentile of women with
no clinical criteria n1 = number of women with at least one criterion n2 = number of women with at least two criteria.
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currence of hirsutism reflect one of the difficulties in
standardizing diagnostic criteria for PCOS and the con-
sequent need for local studies.
The rates of oligomenorrhea/amenorrhea reported in
previous studies on PCOS vary greatly, ranging from
11.9% to 46.5%. The figure found in this study is among
the lowest found (12.9%).
Mean total testosterone levels and the mean LH/FSH
ratio increased in a progressive gradient as a function of
the number of clinical criteria presented by the partici-
pants. These data are consistent with the findings of
Kumarapeli et al., who reported the lowest testosterone
levels in controls followed by probable cases (one criter-
ion) and the highest levels in confirmed PCOS cases (at
least two criteria) [11]. Chen et al. evaluated the clinical
aspects of PCOS and reported higher LH/FSH ratios in
women with two criteria compared to those with just
one [12].
In the present study, a positive correlation was found
between PCOS and height; however, statistical signifi-
cance was lost following adjustment for age (Table 2),
since the participants with PCOS were younger and it
has already been shown that there is a tendency towards
increased stature in younger generations [35]. Neverthe-
less, in an earlier publication, Dessel et al. reported
higher serum levels of the free fraction of insulin growth
factor (IGF-1) in women with PCOS compared to a con-
trol group and lower levels of IGF-1 binding protein
(IGFBP-1) [36]. Garcia-Rudaz et al. reported regular pul-
satility patterns and higher levels of growth hormone se-
cretion in non-obese women with PCOS, similar to
those found in males [37]. These findings permit specu-
lation that these biochemical modifications may increase
the stature of women with PCOS. Future studies should
be designed for the specific purpose of testing this
hypothesis.
PCOS in Brazil and its sociocultural aspects
This is the first study on the prevalence of PCOS to be
conducted either in Brazil or South America. Using the
criteria defined in the RC, the methodology applied was
shown to be appropriate for the screening and diagnosisof this syndrome in primary healthcare services, opening
a gateway to the possibility of implementing clinical pro-
tocols to identify cases of PCOS at primary healthcare
level.
The objective of this study was not to examine the po-
tential effects of the vast socioeconomic differences that
exist in Salvador on the occurrence of PCOS, since the
study was conducted exclusively among adult female
users of the public healthcare network. Women who do
not use the healthcare services, those attending out-
sourced services of the National Health System and
women who use supplementary or private healthcare
services were not included in this sample. The latter
group represents the most economically affluent sector
of the population and is a minority. Although this sam-
ple is limited, it is fairly representative of the population
of Salvador with regard to ethnic composition, education
level and income [38,39].
Nevertheless, this apparent homogeneity harbors a
surprising finding: the higher education level of the
women with PCOS compared to controls, even when
adjusted for age (Table 2). There was also a positive
trend for better education levels within the PCOS group
(p = 0.00) (Table 3). A possible explanation for this asso-
ciation may lie in the fact that women with PCOS have
fewer children, which may have given them a better op-
portunity to advance their education. This would con-
firm reports of an inverse relationship between
schooling and parity that has been widely reported in
the literature. Furthermore, a study carried out in Brazil
[40] confirms that schooling is associated with greater
care in reproductive life, later sexual debut and fewer
children, possibly explaining part of the effect found in
the present study. Exploring socioeconomic status in
women with PCOS, Merkin et al. recently found that the
risk of the syndrome and its components is higher in the
presence of a combined effect of poor parental educa-
tion/high personal education [41].
Conclusions
This was the first study conducted in Brazil or South
America to estimate the prevalence of PCOS in a ran-
dom population. The prevalence rate found was 8.5%
Gabrielli and Aquino Reproductive Biology and Endocrinology 2012, 10:96 Page 9 of 10
http://www.rbej.com/content/10/1/96(95%CI: 6.80 - 10.56). This paper also describes some
interesting and unusual findings such as higher stature
and a higher education level in these women, which
should be addressed in future studies with appropriate
designs. The available literature on PCOS emphasizes
clinical and physiopathological aspects. Further studies
encompassing sociocultural aspects of this syndrome
must be carried out, focusing on questions related both
to its causality and to its consequences on social trajec-
tories, elements that may enrich the understanding of
the phenomenon and its effect on the life of women
affected by the syndrome.
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